Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service, Trade Show

Aurora Bio, Inc. Announces Clinical Data on Lead Program, AUR01, a Novel Systemic Amyloidosis Imaging Tracer, at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition

Aurora Bio, Inc. www.Aurorabioinc.com today announced that data for the company's novel PET radiotracer, AUR01, in development for systemic amyloidosis, has been accepted for presentation at the upcoming 61st American Society of Hematology (ASH) annual meeting, to be held December 7 ? 10, 2019, in Orlando, FL. Abstract highlights and presentation details are outlined below.

Spencer Guthrie, Chief Executive Officer, stated, "We are looking forward to an exciting ASH conference as we present our initial data highlighting the unique ability of AUR01 to detect and potentially monitor whole body amyloid burden in systemic amyloid diseases. The unmet need for early and accurate diagnosis for systemic amyloidosis is significant as many patients are getting diagnosed too late to obtain optimal benefit from treatment. There is currently no approved diagnostic, no agent that can detect whole body amyloid burden and no method for directly measuring change in amyloid pathology in treated patients. We believe this compound has the potential to change the way systemic amyloidosis is diagnosed and monitored and holds great potential to provide for efficient drug development for new targeted therapeutics, including Aurora Bio's own therapeutic programs."

Poster Presentation: https://ash.confex.com/ash/2019/webprogram/Paper128850.html

Presentation Details

3034 Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124I-p5+14, for Imaging Systemic Amyloidosis


Aurora Bio is a clinical stage biopharmaceutical company developing a platform of immunotherapies and an imaging diagnostic for multiple systemic amyloid diseases, including AL, ATTR and ALECT2 amyloidosis. The diagnostic imaging agent is currently in Phase 1 with a planned Ph 3 to potentially initiate in 2020. The company also has 2 pre-clinical stage therapeutic programs being developed for a broad range of systemic amyloid diseases. The immunotherapies consist of a peptide-fusion protein as well as cell therapy utilizing engineered macrophages (CAR-M) to remove amyloid. Currently, there are no approved treatments for 29 out of 30 systemic amyloid diseases While approved therapies in ATTR, and those in development for AL an ATTR, target the pre-cursor protein of individual amyloid diseases, Aurora Bio's goal is to develop immunotherapies that treat across all systemic amyloid diseases. Aurora Bio, Inc. is based in South San Francisco, CA www.aurorabioinc.com

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

These press releases may also interest you

at 00:00
SPS is proud to introduce CMI+, Customized Module Image Plus, a new security feature dedicated to ID documents that consists in including the coat of arms or other government emblems or symbols on the card's micro module. This is done by removing...

at 00:00
R3 International is now offering stem cell therapy for Alzheimers dementia in Mexico with a new program featuring up to 200 million stem cells. Depending on the patient's condition, treatment may be offered IV, intrathecal or with a combination. A...

5 jui 2020
Riiid, a member company of the Born2Global Centre, could not be coming to America at a better time, as artificial intelligence transforms the global education landscape in 2020. Riiid Labs is the global arm of parent company Riiid and has been...

5 jui 2020
HitGen Inc. (HitGen, 688222.SH) announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen's industry-leading DNA-encoded...

5 jui 2020
V-Key announced that V-OS, V-Key's core patented technology, is the world's first virtual secure element to receive a Common Criteria Evaluation Assurance Level (EAL) rating of 3+, derived from the U.S. Government's Protection Profile for General...

5 jui 2020
Air Products , a world leader in industrial gases megaproject development, and thyssenkrupp Uhde Chlorine Engineers, the world leader in technologies and comprehensive solutions for large-scale electrolysis plants, today announced the signing of a...

News published on 22 november 2019 at 14:20 and distributed by: